| ProKidney Reports First Quarter 2025 Financial Results and Business Highlights |
WINSTON-SALEM, N.C., May 12, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today reported financial results and business highlights for the first quarter ended March 31, 2025. |
globenewswire.com |
2025-05-12 20:15:00 |
Czytaj oryginał (ang.) |
| Down -38% in 4 Weeks, Here's Why You Should You Buy the Dip in PROKIDNEY CP (PROK) |
PROKIDNEY CP (PROK) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term. |
zacks.com |
2025-03-21 12:55:33 |
Czytaj oryginał (ang.) |
| ProKidney Reports Full Year 2024 Financial Results and Business Highlights |
WINSTON-SALEM, N.C., March 17, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced financial results and business highlights for the year ended December 31, 2024. |
globenewswire.com |
2025-03-17 09:30:00 |
Czytaj oryginał (ang.) |
| Kuehn Law Encourages Investors of ProKidney Corp. to Contact Law Firm |
NEW YORK , Jan. 31, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of ProKidney Corp. (NASDAQ: PROK) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. |
prnewswire.com |
2025-01-31 13:08:00 |
Czytaj oryginał (ang.) |
| 2025 Will Be A Major Year For ProKidney's Rilparencel In CKD Treatment |
Rilparencel is ProKidney's main candidate. It is intended as a therapy that stabilizes kidneys, making it potentially useful for CKD patients. We'll have Rilparencel's Phase 2 full data in 2025, as well as the potential confirmation about a “surrogate” endpoint for its Phase 3 trials. Currently, Rilparencel's Phase 3 is planned to deliver full data by Q3 2027 if no surrogate endpoint is found that's suitable for the FDA. |
seekingalpha.com |
2025-01-31 08:10:27 |
Czytaj oryginał (ang.) |
| ProKidney to Participate in Two Upcoming Conferences: Evercore HealthCONx Conference and the Citi Global Healthcare Conference |
WINSTON-SALEM, N.C., Nov. 26, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a late clinical-stage biotech company focused on the development of a first-in-class cell therapy candidate for chronic kidney disease (CKD), today announced that senior members of the management team will be participating in the following two upcoming healthcare conferences in December: |
globenewswire.com |
2024-11-26 09:30:00 |
Czytaj oryginał (ang.) |
| ProKidney Reports Third Quarter 2024 Financial Results along with Regulatory and Clinical Development Updates Following Successful FDA Type B Meeting |
WINSTON-SALEM, N.C., Nov. 12, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today reported financial results for the third quarter ended September 30, 2024, and gave several regulatory and clinical development updates. |
globenewswire.com |
2024-11-12 09:30:00 |
Czytaj oryginał (ang.) |
| ProKidney to Participate in the Guggenheim Inaugural Healthcare Innovation Conference and the Jefferies London Healthcare Conference |
WINSTON-SALEM, N.C., Nov. 05, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a late clinical-stage biotech company focused on the development of a first-in-class cell therapy candidate for chronic kidney disease (CKD), today announced that senior members of the management team will be participating in two upcoming healthcare conferences in November. |
globenewswire.com |
2024-11-05 09:30:00 |
Czytaj oryginał (ang.) |
| ProKidney Announces Five Abstracts Selected for Presentation at the American Society of Nephrology's Kidney Week 2024 |
WINSTON-SALEM, N.C., Oct. 14, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced that the Company will present five posters, including one late-breaking clinical trial, at the upcoming American Society of Nephrology's (ASN) Kidney Week being held on October 23-27, 2024, in San Diego, CA. |
globenewswire.com |
2024-10-14 11:30:00 |
Czytaj oryginał (ang.) |
| ProKidney to Participate in the UBS Virtual Organ Restoration Day |
WINSTON-SALEM, N.C., Oct. 09, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a late clinical-stage biotech company focused on the development of a first-in-class cell therapy candidate for chronic kidney disease (CKD), today announced that senior members of the management team will be participating in the UBS Virtual Organ Restoration Day, which will be taking place on October 15, 2024. |
globenewswire.com |
2024-10-09 11:30:00 |
Czytaj oryginał (ang.) |
| ProKidney Announces Strategic Updates to its Phase 3 Program to Accelerate Rilparencel's Registrational Path to Potential Approval in the U.S. |
WINSTON-SALEM, N.C., Sept. 03, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a late clinical-stage biotech company focused on the development of a first-in-class cell therapy candidate for chronic kidney disease (CKD), today announced strategic updates to its Phase 3 program for rilparencel, an investigational treatment to potentially preserve kidney function in patients with type 2 diabetes and advanced CKD. |
globenewswire.com |
2024-09-03 11:30:00 |
Czytaj oryginał (ang.) |
| ProKidney to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference |
WINSTON-SALEM, N.C., Aug. 27, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage biotech company focused on the development of a first-in-class cell therapy candidate for chronic kidney disease (CKD), today announced that senior members of the management team will be participating in the Morgan Stanley 22nd Annual Global Healthcare Conference, being held in New York, NY on September 4-6, 2024. |
globenewswire.com |
2024-08-27 11:30:00 |
Czytaj oryginał (ang.) |
| ProKidney Reports Business Updates and Second Quarter 2024 Financial Results |
WINSTON-SALEM, N.C., Aug. 09, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today reported business updates and financial results for the second quarter ended June 30, 2024. |
globenewswire.com |
2024-08-09 11:00:00 |
Czytaj oryginał (ang.) |
| Play Likely Earnings Beat With 3 Top-Ranked Stocks |
Top-ranked stocks Wingstop (WING), Burlington Stores (BURL) and Prokidney CP (PROK) are likely to beat on the bottom line in their upcoming releases. |
zacks.com |
2024-06-21 11:55:17 |
Czytaj oryginał (ang.) |
| ProKidney Announces Pricing of its Upsized $130 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct Offering |
WINSTON-SALEM, N.C., June 11, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease, today announced the pricing of an underwritten public offering and a concurrent registered direct offering of 53,719,009 shares of its Class A ordinary shares at a price of $2.42 per share, before applicable underwriting discounts and commissions. In addition, the underwriters will have a 30-day option to purchase up to an additional 15% of the Class A ordinary shares sold in the underwritten public offering. All of the Class A ordinary shares in the underwritten public offering and concurrent registered direct offering are being sold by the Company. The public offering and the concurrent registered direct offering are each expected to close on or about June 13, 2024, subject to customary closing conditions. The underwritten public offering is not contingent on the closing of the concurrent direct offering, and the concurrent direct offering is not contingent on the closing of the underwritten public offering. |
globenewswire.com |
2024-06-12 01:35:00 |
Czytaj oryginał (ang.) |
| ProKidney Announces Proposed $125 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct Offering |
WINSTON-SALEM, N.C., June 10, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease, today announced that it has commenced an underwritten public offering and a concurrent registered direct offering of up to an aggregate of $125 million of its Class A ordinary shares, before deducting underwriting discounts and commissions and other offering expenses. ProKidney expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the Class A ordinary shares sold in the underwritten public offering. All of the Class A ordinary shares in the underwritten public offering and concurrent registered direct offering are being sold by the Company. |
globenewswire.com |
2024-06-10 20:15:00 |
Czytaj oryginał (ang.) |
| ProKidney Announces Positive Interim REGEN-007 Phase 2 Trial Data and Provides Clinical and Operational Updates |
WINSTON-SALEM, N.C., June 10, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced positive interim results from the Phase 2 REGEN-007 trial evaluating the Company's renal autologous cell therapy, rilparencel, in patients with CKD caused by diabetes and provided clinical and operational updates. Management will host a live webcast today at 8:00 a.m. ET to discuss the data. |
globenewswire.com |
2024-06-10 10:30:00 |
Czytaj oryginał (ang.) |
| ProKidney to Participate in the Jefferies Global Healthcare Conference |
WINSTON-SALEM, N.C., May 29, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced that senior members of the management team will be participating in the Jefferies Global Healthcare Conference taking place from June 4 – 6, 2024 in New York, NY. |
globenewswire.com |
2024-05-29 11:00:00 |
Czytaj oryginał (ang.) |
| ProKidney to Host Virtual KOL Event to Discuss Current Treatment Landscape of Chronic Kidney Disease Caused by Diabetes and Data from Phase 2 RMCL-002 Clinical Trial on May 28, 2024 |
WINSTON-SALEM, N.C., May 21, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), will host a virtual KOL event on Tuesday, May 28, 2024 at 8:00 AM ET, featuring Steven G. Coca, DO, MS (Icahn School of Medicine at Mount Sinai) and Arnold L. Silva, MD, PhD (University of Arizona) who will discuss the unmet medical need and current treatment landscape for patients with moderate to severe CKD caused by diabetes as well as the importance of preserving kidney function in this patient population. To register, click here . |
globenewswire.com |
2024-05-21 11:00:00 |
Czytaj oryginał (ang.) |
| ProKidney Reports Business Updates and First Quarter 2024 Financial Results |
WINSTON-SALEM, N.C., May 10, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today reported business updates and financial results for the first quarter ended March 31, 2024. |
globenewswire.com |
2024-05-10 11:00:00 |
Czytaj oryginał (ang.) |
| ProKidney Announces Key Leadership Appointments Strengthening Clinical and Technical Operations |
Dr. Ulrich Ernst joins as Executive Vice President of Technical Operations with a deep background and expertise in process development and manufacturing of cell therapies |
globenewswire.com |
2024-03-25 08:05:00 |
Czytaj oryginał (ang.) |
| ProKidney Reports Full Year 2023 Financial Results and Recent Corporate Highlights |
WINSTON-SALEM, N.C., March 21, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced financial results for the year ended December 31, 2023. |
globenewswire.com |
2024-03-21 21:49:00 |
Czytaj oryginał (ang.) |
| ProKidney to Participate in Jefferies Biotech on the Bay Summit |
WINSTON-SALEM, N.C., Feb. 29, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced that senior members of the management team will be participating in the Jefferies Biotech on the Bay Summit being held in Miami on March 12 – 13, 2024. |
globenewswire.com |
2024-02-29 18:05:00 |
Czytaj oryginał (ang.) |
| Here's Why ProKidney Corp. (PROK) Is a Great 'Buy the Bottom' Stock Now |
ProKidney Corp. (PROK) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term. |
zacks.com |
2023-12-13 13:17:32 |
Czytaj oryginał (ang.) |
| ProKidney Appoints Nikhil Pereira-Kamath, MBA, as Chief Business Officer |
Former CEO of Africa Healthcare Network brings extensive understanding of kidney disease to ProKidney Former CEO of Africa Healthcare Network brings extensive understanding of kidney disease to ProKidney |
globenewswire.com |
2023-11-30 08:05:00 |
Czytaj oryginał (ang.) |